Abstract

) The Missouri Valley Cancer Consortium (MVCC) is a multi-component community-based cancer research effort based in Omaha and Lincoln, Nebraska. The catchment area includes western Iowa and east-central Nebraska. The 1990 population was about 1.2 million. The MVCC is the third largest accruer of patients to cancer treatment protocols and the second largest to cancer control protocols in the North Central Cancer Treatment Group. The four main components of the MVCC are Alegent Health Bergan Mercy Medical Center, Alegent Health Immanuel Medical Center, Lincoln Cancer Center, and Creighton University. These institutions have had an established research program with the North Central Cancer Treatment Group (NCCTG) since 1983. Numerous investigators (52) participate and are responsible for over 3200 new cancer patients annually. Over the past 2 years of the previous funding period, these investigators have entered 201.1 and 223.4 patients on NCI-approved cancer treatment and control trials, respectively. The proposed principal and associate principal investigators of the MVCC are currently directing the conduct of the Breast Cancer Prevention Trial and the Prostate Cancer Prevention Trial (837 enrolled and 639 randomized for the state of Nebraska. Previous research base affiliations with NCCTG, ECOG, and NSABP would continue with the addition of RTOG and GOG and enable the future support of this high level of accrual as a NCI-funded CCOP.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA063849-06
Application #
2895126
Study Section
Special Emphasis Panel (ZCA1-RLB-7 (J2))
Program Officer
Parnes, Howard L
Project Start
1994-09-30
Project End
2002-05-31
Budget Start
1999-06-01
Budget End
2000-05-31
Support Year
6
Fiscal Year
1999
Total Cost
Indirect Cost

  Institution

Name
Missouri Valley Cancer Consortium, Inc.
Department
Type
DUNS #
City
Omaha
State
NE
Country
United States
Zip Code
68106

  Publications

Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Rule, William G; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. J Geriatr Oncol 6:119-26
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Dy, Grace K; Molina, Julian R; Qi, Yingwei et al. (2014) NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. J Thorac Oncol 9:1146-53
Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27

Showing the most recent 10 out of 138 publications